Doctors across multiple countries are flagging a painful new COVID-19 symptom tied to a fast-spreading variant: a sore throat so severe that patients compare it to swallowing razor blades. The symptom has emerged alongside the rise of the NB.1.8.1 variant, informally called “Nimbus,” which the World Health Organization now classifies as a Variant Under Monitoring. With global test positivity climbing and the variant accounting for a growing share of sequenced cases, the development has caught the attention of clinicians and public health agencies at a moment when many people had stopped thinking about COVID altogether.
The warning is not that Nimbus is causing dramatically more hospitalizations or deaths than previous waves. Current evidence does not show a clear jump in overall severity. Instead, doctors say the variant is reshaping how COVID feels at the individual level. Patients who might once have described a mild scratchiness now report throat pain so intense that swallowing, speaking, or even drinking water becomes difficult. Those reports, combined with signs of increasing transmission in global surveillance data, are prompting renewed calls for testing, masking in high-risk settings, and attention to vaccination, especially among older adults and people with underlying conditions.
The “Razor Blade” Throat and What Doctors Are Seeing
Sore throats have been part of the COVID-19 symptom profile since the early pandemic years. The World Health Organization lists throat pain among typical COVID symptoms, and the CDC’s clinical guidance notes that COVID-19 symptoms alone are nonspecific, meaning they overlap heavily with influenza and other respiratory infections. What sets the current reports apart is intensity. Clinicians in multiple countries have described patients presenting with throat pain far beyond the typical scratchiness, using the shorthand “razor blade” sore throat to convey the level of distress. The phrase has appeared in news coverage quoting physicians treating patients infected with the Nimbus variant.
The distinction matters for anyone trying to figure out whether a winter sore throat warrants a COVID test. Standard guidance from the CDC stresses that symptoms alone cannot confirm or rule out infection and that testing remains essential, especially for people at higher risk of severe disease. But when a symptom that was previously mild or moderate in most cases suddenly becomes debilitating, it changes patient behavior. People who might have dismissed a scratchy throat are now showing up at clinics, and doctors say the severity is what prompted them to speak up publicly. In some practices, the “razor blade” description has become a shorthand flag for clinicians to prioritize testing and consider early antiviral treatment in eligible patients.
How the Nimbus Variant Gained Ground Globally
The variant behind the symptom shift carries the technical designation NB.1.8.1, but it is widely known as the Nimbus strain. It is not the only new lineage circulating. A related variant called Stratus has also been identified, and both have been linked to rising case counts in several regions. Nimbus, however, has drawn the most clinical attention because of its rapid growth in sequencing data and its apparent association with the unusually painful throat symptom, even as overall patterns of hospitalization have not dramatically shifted.
The WHO’s global surveillance data tells a clear story of acceleration. As of mid-May 2025, sentinel test positivity had reached about 11% in dozens of countries, and NB.1.8.1 accounted for 10.7% of sequenced cases worldwide. The WHO designated NB.1.8.1 a Variant Under Monitoring, a classification that signals the agency is tracking its growth and watching for signs of increased severity or immune evasion. In a late May 2025 update, WHO officials tied increased COVID-19 activity in parts of the world directly to the variant’s spread and discussed how existing vaccines were still expected to provide protection against severe outcomes, according to reporting on the agency’s assessment. That balance (faster spread and notable symptoms, but no confirmed leap in lethality) helps explain why Nimbus is being watched closely rather than treated as an emergency on the scale of earlier waves.
Why Symptom Severity May Be Shifting
One question that clinicians and researchers have not yet answered definitively is why NB.1.8.1 appears to produce more intense throat inflammation than earlier variants. No peer-reviewed study has yet established a direct mechanism, and U.S.-specific clinical datasets have not conclusively linked the Nimbus variant with heightened throat symptoms in a way that rules out other explanations. The absence of that primary research is a gap worth acknowledging. What exists so far is a pattern of consistent anecdotal reports from doctors in different countries, all describing the same unusually severe presentation in patients who test positive for the variant.
One plausible hypothesis, though still unconfirmed, centers on the possibility that NB.1.8.1 has enhanced tropism for mucosal tissue in the upper airway. If the variant replicates more aggressively in the throat lining than its predecessors, that could explain why patients experience sharper pain even when their overall illness remains moderate. Another factor may be population immunity: many people now have a mix of vaccine- and infection-induced protection that blunts fever and lung involvement but may not prevent robust viral replication in the upper airway. Testing these ideas would require comparative viral load analysis of throat swabs collected during different variant waves, along with careful symptom scoring. Until that data arrives, the “razor blade” label remains a clinical observation rather than a confirmed pathological feature of the variant, though the consistency of reports across geographic boundaries gives the observation more weight than a single anecdote would.
What U.S. Surveillance Systems Are Tracking
In the United States, public health officials rely on several overlapping surveillance tools to detect shifts in respiratory virus activity. The CDC’s respiratory virus data channel incorporates wastewater monitoring, emergency department visit data, and outpatient illness reporting through systems like ILINet, as described in the agency’s technical guidance for COVID. Wastewater surveillance, in particular, can detect viral trends before clinical testing catches up, because it captures signals from people who never seek medical care or take a home test. Rising wastewater levels in a region, even without a corresponding spike in hospitalizations, can alert officials that a more transmissible variant such as Nimbus is gaining ground.
On the clinical side, the CDC also maintains a public repository of briefings and educational materials that summarize current trends for health professionals. These updates help clinicians interpret what they are seeing in their own exam rooms, such as clusters of patients with severe sore throat, and place those observations in the context of national data. When a Variant Under Monitoring begins to dominate sequencing, surveillance systems can also guide decisions about when to recommend masking in healthcare settings, how aggressively to promote booster campaigns, and whether to adjust testing strategies in emergency departments and urgent care clinics.
What Patients Can Do if Symptoms Strike
For individuals, the emergence of a “razor blade” sore throat linked to Nimbus does not fundamentally change the core advice about COVID, but it does raise the stakes for paying attention to symptoms. Anyone experiencing a sudden, intense throat pain (especially if it is accompanied by fever, fatigue, congestion, or loss of taste and smell) should consider testing for COVID-19, particularly if they have recently been in crowded indoor settings or around someone who is ill. People at higher risk of complications, including older adults, those with chronic medical conditions, and people who are immunocompromised, are urged to contact a healthcare provider promptly, as early antiviral treatment is most effective when started soon after symptom onset.
Preventive steps remain familiar but important. Staying up to date on vaccination, including recommended boosters, continues to reduce the risk of severe disease even as the virus evolves. Public health agencies emphasize that while variants like Nimbus may partially evade infection-blocking immunity, vaccines still bolster the body’s defenses against hospitalization and death. In crowded indoor environments or when visiting high-risk loved ones, wearing a well-fitted mask and improving ventilation can lower the odds of transmission. For those who do become ill, isolating while contagious, drinking plenty of fluids despite the throat discomfort, and using over-the-counter pain relievers as advised by a clinician can help manage symptoms while protecting others. As Nimbus spreads, the combination of vigilant surveillance and individual precautions will shape how disruptive this latest phase of the pandemic becomes.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
